40Hz感官刺激诱导伽马振荡增强脑网络连接改善卒中后认知障碍:中国前瞻性随机对照试验方案
本研究为在中国开展的前瞻性随机对照双盲非劣效试验,计划纳入120例卒中后3至6个月持续认知障碍患者,1:1随机接受40Hz感官刺激或随机频率感官刺激,两组均接受标准药物治疗和康复。主要终点为认知功能与学习能力,次要终点包括脑血流动力学、神经网络连接、突触相关基因表达和神经递质水平,并评估安全性。
要点
- 40Hz感官刺激可能改善卒中后认知障碍患者的认知功能与学习能力。
- 试验将评估脑血流、网络连接、突触基因表达等潜在机制。
- 安全性监测包括主要不良事件、全因死亡和光敏性癫痫。
核心结论
- 本研究将评估40Hz感官刺激诱导伽马振荡治疗卒中后认知障碍的安全性和有效性,并探索突触相关基因和神经网络连接等潜在机制。
研究设计与样本
- 前瞻性、随机对照、双盲、非劣效试验,在中国上海中医药大学附属第七人民医院开展。
- 计划纳入120例卒中后3至6个月持续认知障碍患者,按1:1随机分为40Hz感官刺激组和随机频率感官刺激组。
- 两组均接受相同的标准临床药物治疗和康复治疗,评估时间为基线、14天治疗结束后以及3个月和6个月随访。
关键数值与推荐
- 主要疗效终点包括认知功能和学习能力。
- 次要终点包括脑血流动力学、神经网络连接、突触相关基因表达和神经递质水平的变化。
- 安全性评估包括主要不良事件、全因死亡和光敏性癫痫的监测。
临床怎么用
- 若试验证实有效,40Hz感官刺激可作为卒中后认知障碍的辅助治疗手段,联合标准药物和康复治疗使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poststroke cognitive impairment (PSCI) has an incidence rate ranging from 24% to 80.97%. It reduces survival rates and increases disability among stroke patients, posing a substantial socioeconomic burden. Current treatments for PSCI primarily involve medication and rehabilitation; however, therapeutic efficacy remains limited, with unsatisfactory improvement in activities of daily living. This study aims to conduct a prospective clinical trial to evaluate the safety and efficacy of 40-Hz sensory stimulation-induced gamma oscillations in the treatment of PSCI, including assessment of neuropsychology, psychiatric symptoms, cerebral blood perfusion, and functional and structural brain changes, and to investigate the underlying mechanisms by RNA-sequencing of blood samples. METHODS: This trial is designed as a prospective, randomized controlled, double-blind, non-inferiority study conducted in the Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine in China. Participants with confirmed cognitive impairment occurring after the stroke event and persisting for 3 to 6 months will be screened and recruited by the attending neurologists for participation. A total of 120 enrolled patients will be randomly assigned to one of two groups at a ratio of 1:1. The experimental group will receive 40-Hz sensory stimulation, while the control group will receive sensory stimulation at random frequencies. Both groups will receive the same standard clinical drug therapy and rehabilitation treatment. The primary efficacy endpoints include cognitive function and learning ability. Secondary endpoints encompass changes in cerebral hemodynamics, neural network connectivity, synaptic-related gene expression, and neurotransmitter levels. Safety assessments will include monitoring of major adverse events, all-cause mortality, and photosensitive epilepsy. Evaluations will be conducted at baseline, after the 14-day treatment period, and during follow-up visits (at 3 and 6 months). Differences between the two groups will be compared. DISCUSSION: This study will assess the safety and efficacy of gamma oscillations induced by 40-Hz sensory stimulation in treating PSCI patients. In parallel, potential mechanisms-including alterations in synaptic-related genes and neural network connectivity-will be explored. This trial is expected to provide evidence supporting the effectiveness of this novel technique for treating PSCI and improving patients' quality of life. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR) ChiCTR2400088535. Registered on 20 August 2024.
引用
- Fu W, Wang Y, Shi J, et al. 40-Hz sensory stimulation-induced gamma oscillations enhancing brain network connectivity to improve poststroke cognitive impairment: study protocol for a prospective randomized controlled trial in China. Trials. 2026. PMID: 41742294. doi:10.1186/s13063-026-09562-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。